• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

MUMBAI: J.B. Chemicals & Pharmaceuticals Ltd (JBCPL) has received regulatory approval to sell the generic version of anti-fungal drug Fluconazole in the US.

The company said that it received the US Food and Drug Administration approval to manufacture and market Fluconazole tablets in the US market. The total market size of Fluconazole tablets in the US is about $610 million.

JBCPL is the third Indian company to receive the approval for this product. The company already has US FDA approval to manufacture and market ciprofloxacin tablets in the US market, a company statement said.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Yamaha spins off new sales, marketing subsidiary

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line